609 results on '"Gordon, Kenneth B."'
Search Results
2. Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis
3. Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials
4. Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials
5. Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review
6. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial
7. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
8. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial
9. Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures
10. Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2).
11. Cutaneous Manifestations of Chronic Liver Disease
12. Bimekizumab 3-year Maintenance of Response in Week 16 Responders with Moderate to Severe Plaque Psoriasis: Results from Five Phase 3/3b Trials
13. Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study
14. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study
15. Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis
16. Contributors
17. Tumor Necrosis Factor Inhibitors
18. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
19. Bimekizumab safety in patients with moderate to severe plaque psoriasis: Pooled data from up to three years of treatment in randomized phase 3 trials
20. Biologic Therapies for Psoriasis
21. Diagnosis and evaluation of psoriasis and psoriatic arthritis
22. Residual Lesional Gene Expression in Psoriasis Patients with Complete Skin Clearance Treated with Guselkumab or Adalimumab in VOYAGE 1 and 2
23. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary
24. Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program
25. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
26. Synthesis and Conclusion
27. Psoriasis
28. HIGHLIGHTS OF Skin Disease Education Foundation's 42nd Annual Hawaii Dermatology Seminar[R] Grand Hyatt Kauai, Hawaii; February 4-9, 2018
29. The Evolving Landscape of Psoriasis Treatment
30. Practical Strategies for Optimizing Management of Psoriasis
31. Treating to Target--A Realistic Goal in Psoriasis?
32. Common and Not-So-Common Comorbidities of Psoriasis
33. Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials
34. Deucravacitinib in moderate-to-severe psoriasis
35. Anti-IL 23 biologics for the treatment of plaque psoriasis
36. 32953 Efficacy responses across disease severity and treatment history subgroups of patients with moderate to severe plaque psoriasis treated with guselkumab: Pooled results from VOYAGE 1&2 through 5 years
37. 33028 Direct and indirect treatment effect of guselkumab on anxiety and depression in patients with psoriasis by adjusting for Psoriasis Area and Severity Index (PASI) – A mediation analysis
38. 34914 Long-term safety of risankizumab in patients with psoriatic disease: Findings from integrated analyses of 17 clinical trials in psoriasis and 4 in psoriatic arthritis
39. 31085 Bimekizumab early treatment response translates into cumulative benefits in health-related quality of life in patients with moderate to severe plaque psoriasis: Pooled results from three multicenter, randomized, double-blinded phase 3 trials
40. 52671 Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
41. 51349 Spesolimab for the prevention of generalized pustular psoriasis (GPP) flares in White/Caucasian patients: Results from the randomized, placebo-controlled Effisayil 2 study
42. Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials
43. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis
44. Chemoprevention of Skin Cancer
45. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
46. Definitions of Measures of Effect Duration for Psoriasis Treatments
47. Unmet needs in the treatment of psoriasis
48. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials
49. Anti-p40 Antibodies Ustekinumab and Briakinumab: Blockade of Interleukin-12 and Interleukin-23 in the Treatment of Psoriasis
50. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.